Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare
 
> Favipiravir [259793-96-9]

Favipiravir [259793-96-9]

Stampa Stampa
Entra

Cat# 10-4471-50mg

Size : 50mg

Marca : Focus Biomolecules

Richiedere ulteriori informazioni

Contatta il distributore locale :


Telefono : +1 850 650 7790

Favipiravir | Inhibitor of viral RNA-dependent RNA polymerase

CAS:
259793-96-9
Catalog Number:
10-4471
Activity:
Inhibitor of viral RNA-dependent RNA polymerase
Chemical Name:
6-Fluoro-3-hydroxypyrazine-2-carboxamide
Alternate Name:
T-705
Molecular Weight:
157.10
Molecular Formula:
C5H4FN3O2
Solubility:
Soluble in DMSO (30 mg/mL), water (12 mg/mL with warming)
Physical Properties:
Off-white solid
Purity:
>99% by HPLC
NMR (Conforms)
Storage Temperature:
-20°
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or water may be stored at -20° for up to 3 months.
Shipping Code:
RT

Available Options

Size: Quantity 
10 mg$40.00
50 mg$140.00
Request Quote / Bulk / Custom Size
Product Inquiry

Favipiravir (259793-96-9) is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.1,2,3 It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase.4 Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses.5 In clinical trials for treatment of SARS-CoV-2.6,7

References/Citations:

1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977
2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235
3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517
4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981
5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446
6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58
7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21 E2657

CAS:
259793-96-9
Catalog Number:
10-4471
Activity:
Inhibitor of viral RNA-dependent RNA polymerase
Chemical Name:
6-Fluoro-3-hydroxypyrazine-2-carboxamide
Alternate Name:
T-705
Molecular Weight:
157.10
Molecular Formula:
C5H4FN3O2
Solubility:
Soluble in DMSO (30 mg/mL), water (12 mg/mL with warming)
Physical Properties:
Off-white solid
Purity:
>99% by HPLC
NMR (Conforms)
Storage Temperature:
-20°
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or water may be stored at -20° for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a restocking/refund fee

Favipiravir (259793-96-9) is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.1,2,3 It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase.4 Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses.5 In clinical trials for treatment of SARS-CoV-2.6,7

References/Citations:

1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977
2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235
3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517
4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981
5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446
6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58
7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21 E2657